AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (2.8 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article | Open Access

Characterization of antibacterial activity of lytic bacteriophage PE-1 for biological control of Escherichia coli K88 in vitro

Penghao Zhao1Xiangchen Meng1,2( )
College of Food Science, Northeast Agricultural University, Harbin 150030, China
Key Laboratory of Dairy Science, Ministry of Education, Northeast Agricultural University, Harbin 150030, China
Show Author Information

Abstract

In recent years, antibiotic-resistant pathogens have placed tremendous pressure on pathogen control within the livestock industry. Consequently, we have turned our attention to phages, a unique type of virus that has co-evolved with bacteria for an extended period. PE-1 is a bacteriophage strain capable of effectively controlling target pathogens and was isolated from samples collected from dead piglets suffering from intestinal disease and their living environment. Enterotoxigenic Escherichia coli (ETEC) K88 was employed as an inhibitory target to characterize the growth characteristics and in vitro antibacterial effects of bacteriophage PE-1. Morphological analysis tentatively classified phage PE-1 as belonging to the Podoviridae family. The one-step growth curve revealed that phage PE-1 had a short latent period of 10 min, a rise period of 20 min, and a burst size of 13 PFU/cell. The optimal multiplicity of infection (MOI) for phage PE-1 is 10, and the phage maintained normal activity at pH levels between 4−11 and temperatures no higher than 55 °C. Through two in vitro simulated test experiments, we evaluated the antibacterial efficacy of the bacteriophage. Our findings indicated that bacteriophage PE-1 delayed the growth activity of ETEC K88 by more than 2 h and reduced the proliferation rate of the host bacteria under infection conditions. Moreover, the bacteriophage decreased the concentration of host bacteria that reached the stationary phase. After inoculating the host bacteria with the optimal MOI, the host bacteria concentration dropped by nearly three orders of magnitude after 4 h. In conclusion, bacteriophage PE-1 demonstrates potential as an antibacterial agent for ETEC K88.

References

[1]

V. Garcia, M. Gambino, K. Pedersen, et al., F4-and F18-positive enterotoxigenic Escherichia coli isolates from diarrhea of postweaning pigs: genomic characterization, Appl. Environ. Microbiol. 86 (2020) 23. https://doi.org/10.1128/AEM.01913-20.

[2]

S. C. Yang, C. H. Lin, I. A. Aljuffali, et al., Current pathogenic Escherichia coli foodborne outbreak cases and therapy development, Arch. Microbiol. 199 (2017) 811–825. https://doi.org/10.1007/s00203-017-1393-y.

[3]

A. Mirhoseini, J. Amani, S. Nazarian, Review on pathogenicity mechanism of enterotoxigenic Escherichia coli and vaccines against it, Microb. Pathog. 117 (2018) 162–169. https://doi.org/10.1016/j.micpath.2018.02.032.

[4]

T. D. Connell, Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by Type I and Type II heat-labile enterotoxins, Expert Rev. Vaccines 6 (2007) 821–834. https://doi.org/10.1586/14760584.6.5.821.

[5]

A. Luppi, Swine enteric colibacillosis: diagnosis, therapy and antimicrobial resistance, Porc. Health Manag. 3 (2017) 16. https://doi.org/10.1186/s40813-017-0063-4.

[6]

F. Qadri, A. M. Svennerholm, A. S. G. Faruque, et al., Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention, Clin. Microbiol. Rev. 18 (2005) 465–483. https://doi.org/10.1128/CMR.18.3.465-483.2005.

[7]

Y. W. Sun, S. W. Kim, Intestinal challenge with enterotoxigenic Escherichia coli in pigs, and nutritional intervention to prevent postweaning diarrhea, Anim. Nutr. 3 (2017) 322–330. https://doi.org/10.1016/j.aninu.2017.10.001.

[8]
European Medicines Agency, Zinc oxide, (2017). https://www.ema.europa.eu/en/medicines/veterinary/referrals/zinc-oxide.
[9]
V. A. N. Suiryanrayna Mocherla, J. V. Ramana, A review of the effects of dietary organic acids fed to swine, J. Anim. Sci. Biotechnol. 6 (2015) 45. https://doi.org/10.1186/s40104-015-0042-z.
[10]

M. Roselli, R. Pieper, C. Rogel-Gaillard, et al., Immunomodulating effects of probiotics for microbiota modulation, gut health and disease resistance in pigs, Anim. Feed Sci. Technol. 233 (2017) 104–119. https://doi.org/10.1016/j.anifeedsci.2017.07.011.

[11]

J. Zhang, Z. Li, Z. Cao, et al., Bacteriophages as antimicrobial agents against major pathogens in swine: a review, J. Anim. Sci. Biotechnol. 6 (2015) 39. https://doi.org/10.1186/s40104-015-0039-7.

[12]
E. Kutter, A. Sulakvelidze (Eds.), Bacteriophages: biology and applications, CRC Press, Boca Raton, 2004. https://doi.org/10.1201/9780203491751.
[13]

M. De Paepe, F. Taddei, Viruses’ life history: towards a mechanistic basis of a trade-off between survival and reproduction among phages, PLoS Biol. 4 (2006) 1248–1256. https://doi.org/10.1371/journal.pbio.0040193.

[14]

M. R. J. Clokie, A. D. Millard, A. V. Letarov, et al., Phages in nature, Bacteriophage 1 (2011) 31–45. https://doi.org/10.4161/bact.1.1.14942.

[15]

M. K. Mirzaei, C. F. Maurice, Menage a trois in the human gut: interactions between host, bacteria and phages, Nat. Rev. Microbiol. 15 (2017) 397–408. https://doi.org/10.1038/nrmicro.2017.30.

[16]

Y. Hong, Y. Pan, P. D. Ebner, Meat science and muscle biology symposium: development of bacteriophage treatments to reduce Escherichia coli O157:H7 contamination of beef products and produce, J. Anim. Sci. 92 (2014) 1366–1377. https://doi.org/10.2527/jas.2013-7272.

[17]

F. L. G. Altamirano, J. J. Barr, Phage therapy in the postantibiotic era, Clin. Microbiol. Rev. 32 (2019) 2. https://doi.org/10.1128/CMR.00066-18.

[18]

A. Gigante, R. J. Atterbury, Veterinary use of bacteriophage therapy in intensively-reared livestock, Virol. J. 16 (2019) 155. https://doi.org/10.1186/s12985-019-1260-3.

[19]
D. W. Russell, J. Sambrook (Eds.), Molecular cloning: a laboratory manual, ScienceOpen, Inc., 2001.
[20]

Z. Hu, X. C. Meng, F. Liu, Isolation and characterisation of lytic bacteriophages against Pseudomonas spp., a novel biological intervention for preventing spoilage of raw milk, Int. Dairy J. 55 (2016) 72–78. https://doi.org/10.1016/j.idairyj.2015.11.011.

[21]

A. Asif, H. Mohsin, R. Tanvir, et al., Revisiting the mechanisms involved in calcium chloride induced bacterial transformation, Front. Microbiol. 8 (2017) 2169. https://doi.org/10.3389/fmicb.2017.02169.

[22]

S. K. Newase, A. Gupta, S. G. Dastager, et al., Development and evaluation of taxon-specific primers for the selected Caudovirales taxa, Virus Res. 263 (2019) 184–188. https://doi.org/10.1016/j.virusres.2019.02.005.

[23]

S. Sinha, R. K. Grewal, S. Roy, Modeling bacteria-phage interactions and its implications for phage therapy, Adv. Appl. Microbiol. 103 (2018) 103–141. https://doi.org/10.1016/bs.aambs.2018.01.005.

[24]

Z. Lu, F. Breidt, H. P. Fleming, et al., Isolation and characterization of a Lactobacillus plantarum bacteriophage, Phi JL-1, from a cucumber fermentation, Int. J. Food Microbiol. 84 (2003) 225–235. https://doi.org/10.1016/S0168-1605(03)00111-9.

[25]

S. Chakraborty, A. von Mentzer, Y. A. Begum, et al., Phenotypic and genomic analyses of bacteriophages targeting environmental and clinical CS3-expressing enterotoxigenic Escherichia coli (ETEC) strains, PloS ONE 13 (2018) e0209357. https://doi.org/10.1371/journal.pone.0209357.

[26]

G. H. Kim, J. W. Kim, J. Kim, et al., Genetic analysis and characterization of a bacteriophage empty setCJ19 active against enterotoxigenic Escherichia coli, Food Sci. Anim. Resour. 40 (2020) 746–757. https://doi.org/10.5851/kosfa.2020.e49.

[27]

X. Ji, C. Zhang, Y. Fang, et al., Isolation and characterization of glacier VMY22, a novel lytic cold-active bacteriophage of Bacillus cereus, Virol. Sin. 30 (2015) 52–58. https://doi.org/10.1007/s12250-014-3529-4.

[28]

X. Yuan, S. Zhang, J. Wang, et al., Isolation and characterization of a novel Escherichia coli Kayfunavirus phage DY1, Virus Res. 293 (2021) 198274. https://doi.org/10.1016/j.virusres.2020.198274.

[29]

D. W. Park, J. H. Park, Characterization and food application of the novel lytic phage BECP10: specifically recognizes the O-polysaccharide of Escherichia coli O157: H7, Viruses 13 (2021) 8. https://doi.org/10.3390/v13081469.

[30]

P. Sliwka, B. Weber-Dabrowska, M. Zaczek, et al., Characterization and comparative genomic analysis of three virulent E. coli bacteriophages with the potential to reduce antibiotic-resistant bacteria in the environment, Int. J. Mol. Sci. 24 (2023) 6.

[31]

J. J. Bull, K. A. Christensen, C. Scott, et al., Phage-bacterial dynamics with spatial structure: self organization around phage sinks can promote increased cell densities, Antibiotics 7 (2018) 8. https://doi.org/10.3390/antibiotics7010008.

[32]

A. Ross, S. Ward, P. Hyman, More is better: selecting for broad host range bacteriophages, Front. Microbiol. 7 (2016) 1352. https://doi.org/10.3389/fmicb.2016.01352.

[33]
A. Calsina, J. J. Rivaud, A size structured model for bacteria-phages interaction, Nonlinear Anal. Real World Appl. 15 (2014) 100–117. https://doi.org/10.1016/j.nonrwa.2013.06.004.
[34]

M. Jamal, T. Hussain, C. R. Das, et al., Isolation and characterization of a Myoviridae MJ1 bacteriophage against multi-drug resistant Escherichia coli 3, Jundishapur. J. Microbiol. 8 (2015) e25917. https://doi.org/10.5812/jjm.25917.

[35]

Z. Guo, H. Lin, X. Ji, et al., Therapeutic applications of lytic phages in human medicine, Microb. Pathog. 142 (2020) 104048. https://doi.org/10.1016/j.micpath.2020.104048.

[36]

R. Fish, E. Kutter, G. Wheat, et al., Bacteriophage treatment of intransigent diabetic toe ulcers: a case series, J. Wound Care 25(Suppl 7) (2016) S27–S33. https://doi.org/10.12968/jowc.2016.25.7.S27.

[37]

A. M. Comeau, F. Tetart, S. N. Trojet, et al., Phage-antibiotic synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth, PLoS ONE 2 (2007) e799. https://doi.org/10.1371/journal.pone.0000799.

[38]

C. Torres-Barcelo, M. E. Hochberg, Evolutionary rationale for phages as complements of antibiotics, Trends Microbiol. 24 (2016) 249–256. https://doi.org/10.1016/j.tim.2015.12.011.

[39]

W. N. Chaudhry, J. Concepcion-Acevedo, T. Park, et al., Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms, PLoS ONE 12 (2017) e0168615. https://doi.org/10.1371/journal.pone.0168615.

[40]

C. Y. Leung, J. S. Weitz, Modeling the synergistic elimination of bacteria by phage and the innate immune system, J. Theor. Biol. 429 (2017) 241–252. https://doi.org/10.1016/j.jtbi.2017.06.037.

Food Science of Animal Products
Article number: 9240014
Cite this article:
Zhao P, Meng X. Characterization of antibacterial activity of lytic bacteriophage PE-1 for biological control of Escherichia coli K88 in vitro. Food Science of Animal Products, 2023, 1(2): 9240014. https://doi.org/10.26599/FSAP.2023.9240014

791

Views

92

Downloads

0

Crossref

Altmetrics

Received: 23 March 2023
Revised: 10 April 2023
Accepted: 06 May 2023
Published: 28 June 2023
© Beijing Academy of Food Sciences 2023.

Food Science of Animal Products published by Tsinghua University Press. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Return